Status:
COMPLETED
Intravenous Proton Pump Inhibitor for Peptic Ulcer Bleeding
Lead Sponsor:
Lotung Poh-Ai Hospital
Conditions:
Peptic Ulcer Hemorrhage
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
A large dose of PPI is effective in preventing peptic ulcer rebleeding. The investigators hypothesize that 40 mg/q6h pantoloc is equivalent to 8mg/h pantoloc in preventing rebleeding.
Detailed Description
A bleeding peptic ulcer remains a serious medical problem with significant morbidity and mortality. Endoscopic therapy significantly reduces further bleeding, surgery, and mortality in patients with b...
Eligibility Criteria
Inclusion
- Patients were accepted for endoscopic therapy if a peptic ulcer with active bleeding, a non-bleeding visible vessel (NBVV) or an adherent blood clot at the ulcer base was observed within 24 hours of hospital admission.
Exclusion
- If patients were pregnant
- Did not obtain initial hemostasis with endoscopic injection of epinephrine
- Did not give written informed consent
- Had bleeding tendency (platelet count \< 50×109/L, serum prothrombin \< 30% of normal, or were taking anticoagulants), uremia.
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00731601
Start Date
May 1 2008
End Date
April 1 2009
Last Update
April 7 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lotung Poh-Ai hospital
Yilan, Taiwan, 26514